RALEIGH, N.C., Oct. 26 (Korea Bizwire) — PRA Health Sciences (PRA) (NASDAQ:PRAH) is pleased to announce the opening of its brand new, state-of-the-art Bioanalytical Laboratory in Assen, the Netherlands. The 33,000 square foot facility provides 25 percent more space than PRA’s previous lab, includes investments in the newest small and large molecule equipment, and allows for optimal bioanalytical process efficiencies. The new laboratory is also located close to PRA’s Phase I clinics in Groningen and Zuidlaren, providing easy access and analysis of the most time-critical samples and execution of adaptive trials.
“We are proud to offer our clients industry-leading, high quality, high science laboratory services in this new and innovative environment,” said Peter Ketelaar, PRA Vice President of Global Bioanalytical Laboratory Services. “The new facility is a testament to PRA’s commitment to excellence and our passion to advance clinical development.”
PRA bioanalytical laboratories have 30+ years of experience in providing bioanalytical services in support of clinical and pre-clinical trials for both small and large molecules. Industry leading experts with a depth of scientific and regulatory knowledge and experience manage and support PRA’s laboratory services, contributing to successful development of new medicines.
“Our technology investments and innovative services operations are what set PRA apart in the industry,” said PRA CEO Colin Shannon. “We take enormous pride in the expertise we bring to the table that enables us to excel at clinical research and deliver quality results for our clients and patients.”
PRA operates GLP-compliant (Good Laboratory Practice) and fully harmonized bioanalytical laboratories in the Netherlands and the Unites States (Lenexa, Kansas). Both are strategically located near PRA’s clinical research units to enable close collaboration and faster drug development decision making.
ABOUT PRA HEALTH SCIENCES
At PRA Health Sciences, providing innovative solutions for our clients is what we do. Side-by-side with our clients, we strive to move drug discovery forward, helping them to develop life-saving and life-improving drugs. PRA has more than 11,000 employees working in 80+ countries providing comprehensive clinical development services across all phases. From full service clinical development to the pioneering Embedded Solutions™ model, PRA provides a broad spectrum of solutions that meet the demands of a diverse marketplace. PRA has worked on 100+ marketed drugs across several therapeutic areas and conducted the pivotal or supportive trials that led to FDA and/or international regulatory approval of 50+ such drugs.
INQUIRIES: Christine Rogers, Manager – Public Relations, Corporate Communications
EMAIL: email@example.com PHONE: +1 919.786.8463
Source: PRA Health Sciences via GLOBE NEWSWIRE